NRX Pharmaceuticals Inc NRXP

NAS: NRXP | ISIN: US6294441000   31/05/2024
3,810 USD (+3,53%)
(+3,53%)   31/05/2024
Grafiek NRX Pharmaceuticals Inc Grafiek NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc in het nieuws

28 mei 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression · Persbericht

14 mei 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update · Persbericht

8 mei 2024 · NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 · Persbericht

7 mei 2024 · NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024 · Persbericht

6 mei 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression · Persbericht

30 april 2024 · NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression · Persbericht

18 april 2024 · NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement · Persbericht

18 april 2024 · NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock · Persbericht

17 april 2024 · NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock · Persbericht

17 april 2024 · NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections · Persbericht

Profiel NRX Pharmaceuticals Inc

Hoofdzetel: Delray Beach, Florida vlag Verenigde Staten

Werknemers: 4

Aandelen NRX Pharmaceuticals Inc

Beurswaarde: 39,38 miljoen USD

Effecten: 10,70 miljoen

Beta: 1,48

Mijn selecties